Abstract
It has been shown that administration of adipose derived mesenchymal stem cells (AdMSCs) enhanced structural and functional recovery of renal ischemia-reperfusion (IR) injury. Low engraftment of stem cells, however, limits the therapeutic effects of AdMSCs. The present study was designed to enhance the therapeutic effects of AdMSCs by delivering AdMSCs in a three-dimensional (3D) aggregates form. Microwell was used to produce 3D AdMSCs aggregates. In vitro data indicated that AdMSCs in 3D aggregates were less susceptible to oxidative and hypoxia stress induced by 200 μM peroxide and hypoxia/reoxygenation, respectively, compared with those cultured in two-dimensional (2D) monolayer. Furthermore, AdMSCs in 3D aggregates secreted more proangiogenic factors than those cultured in 2D monolayer. 2D AdMSCs or 3D AdMSCs aggregates were injected into renal cortex immediately after induction of renal IR injury. In vivo data revealed that 3D aggregates enhanced the effects of AdMSCs in recovering function and structure after renal IR injury. Improved grafted AdMSCs were observed in kidney injected with 3D aggregates compared with AdMSCs cultured in 2D monolayer. Our results demonstrated that 3D AdMSCs aggregated produced by microwell enhanced the retention and therapeutic effects of AdMSCs for renal IR injury.
Highlights
Mesenchymal stem cells (MSCs) are multipotent progenitor cells which could be isolated from several tissues, in particular bone marrow and adipose tissue [1, 2]
The adipose derived mesenchymal stem cells (AdMSCs) aggregates did not disassemble for culture time up to 14 days
After culture in microwell for 7 days, cells expressed significantly increased the level of fibronectin and laminin (Figures 2(c)–2(e)) compared with 2D cells, partly indicating the significantly increased secretion of extracellular matrix (ECM) in 3D AdMSCs aggregates
Summary
Mesenchymal stem cells (MSCs) are multipotent progenitor cells which could be isolated from several tissues, in particular bone marrow and adipose tissue [1, 2]. The therapeutic effects of MSCs for renal IR injury have been well described, a lack of initial engraftment and retention due to early cell death is a major roadblock to achieving clinical significance [7]. This might be due to the “harsh environment” including oxidative stress, hypoxia in the injured kidney. Several strategies have been developed to improve the survival of engrafted stem cells in ischemic kidney. Despite the improved survival of stem cells in ischemic kidney, the strategies still have problems for further clinical application
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
